James R. Kasinger
2019
In 2019, James R. Kasinger earned a total compensation of $4.2M as General Counsel at CRISPR Therapeutics AG, a 33% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $218,602 |
|---|---|
| Option Awards | $1,688,850 |
| Salary | $376,900 |
| Stock Awards | $1,924,600 |
| Other | $9,800 |
| Total | $4,218,752 |
Kasinger received $1.9M in stock awards, accounting for 46% of the total pay in 2019.
Kasinger also received $218.6K in non-equity incentive plan, $1.7M in option awards, $376.9K in salary and $9.8K in other compensation.
Rankings
In 2019, James R. Kasinger's compensation ranked 2,784th out of 13,971 executives tracked by ExecPay. In other words, Kasinger earned more than 80.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,784 out of 13,971 | 80th |
Division Manufacturing | 1,004 out of 5,701 | 82nd |
Major group Chemicals And Allied Products | 333 out of 2,200 | 85th |
Industry group Drugs | 271 out of 1,886 | 86th |
Industry Biological Products, Except Diagnostic Substances | 65 out of 389 | 83rd |
Source: SEC filing on April 24, 2020.
Kasinger's colleagues
We found four more compensation records of executives who worked with James R. Kasinger at CRISPR Therapeutics AG in 2019.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019